A new generation of weight loss jabs could soon be on the market, thanks to work going on in Zurich.
Working at the Vetsuisse Faculty, Thomas Lutz, studies diabetes in cats - the only animal other than humans that develop type 2 diabetes.
He’s identified a hormone, amylin, in overweight cats and now weight loss jabs are being developed based on it.
It’s hoped the new drugs will be better tolerated, less likely to cause nausea, not affect muscle mass so much and won't suppress appetite too much - but rather make the patient feel full quicker.
The new drugs could be on the market as soon as next year.
Parliament rejects WHO alcohol policy
Cyclist dies near the UN
Govt may buy fewer F-35s due to cost
Amnesty slams Bern police
Two men given house arrest after stealing vignettes
What's likely under the tree this year?
